Here are four observations:
1. NuVasive’s $0.32 EPS for the period ending March 31 checked within $0.05 of Wall Street analysts’ predictions.
2. Price Target Brokerage firm analysts predict NuVasive’s stock will hit $63.916 on a short-term basis.
3. The highest stock estimate reached $76 and the lowest estimate was $58.
4. Zacks gave NuVasive a rating of 1.27 (with one being a “strong buy” and five being a strong sell.”)
More articles on devices:
Open Payments data may need more nuance, S.C. physicians say — 5 notes
Stryker Q2 net sales jump 16.8% to $2.8B: 9 key notes
Zimmer Biomet, Medtronic, DePuy Synthes & more: 16 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
